Evidence map›Paper›PMID 42037670›Full record

ArticleAgeing and cancer research & treatment2026

KCTD10 as a selective cancer dependency from transcription-replication conflicts (TRCs).

Jake A Kloeber, Bin Chen, Robert Mutter, Jinzhou Huang, Zhenkun Lou

Abstract read
In one paragraph

Article in Ageing and cancer research & treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jake A KloeberDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Bin ChenDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Robert MutterDepartment of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA.
Jinzhou HuangDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.
Zhenkun LouDivision of Oncology Research, Mayo Clinic, Rochester, MN 55905, USA.

Funding

Sensitizing Ovarian Cancer To PARP inhibitor and platinum treatmentR01CA264600 · NCI · MAYO CLINIC ROCHESTER · PI LOU, ZHENKUN · 2021 to 2025
$1.8M
Mechanism and therapeutic targeting of castration resistance in SPOP-mutated prostate cancerR01CA285345 · NCI · MAYO CLINIC ROCHESTER · PI Josep Maria Domingo-Domenech, Zhenkun Lou · 2024 to 2026
$1.5M
Ovcoming PARP Inhibitor ResistanceR01CA288753 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou, Liewei Wang · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA264600NCI NIH HHS R01 CA285345NCI NIH HHS R01 CA288753
6 · The paper itself

Abstract

Transcription-replication conflicts (TRCs) are an increasingly recognized driver of genome instability in human cells. We recently identified the CUL3 adaptor KCTD10 as a sensor of co-directional TRCs, recruiting CUL3 to ubiquitinate transcriptional machinery and clear the path for replication forks. Here, we discuss the implications of this conflict-resolution pathway for human cancer. By integrating our mechanistic findings with large-scale functional genomics datasets, we identify oncogenic conditions that potentially create TRC-rich environments and render cells selectively dependent on KCTD10. These contexts reveal new mechanistic insights and potential therapeutic opportunities across a range of human cancers.

Indexed as

cancer therapyDNA replicationgenome stabilityKCTD10transcriptiontranscription-replication conflicts

Identifiers

PMID42037670
PMCPMC13108697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.